B
BRIDGEBIO ONCOLOGY THERAPEUTICS, INC.
NASDAQ: BBOT (BridgeBio Oncology Therapeutics)
Kemas kini terakhir: 8 jam lalu3.89
-0.05 (-1.27%)
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Menaik |
| Biotechnology (Global) | Bercampur | Menaik | |
| Stok | BridgeBio Oncology Therapeutics | Bercampur | Menurun |
AISkor Stockmoo
0.5
| Konsensus Penganalisis | NA |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 3.0 |
| Purata Bergerak Teknikal | 1.0 |
| Osilator Teknikal | -2.5 |
| Purata | 0.50 |
|
BridgeBio Oncology Therapeutics Inc, is a clinical-stage biotechnology company that aims to transform the lives of patients with cancers driven by RAS and PI3Ka, the two frequently mutated oncogenes. The Company operates in one operating and reportable segment within the United States, developing oncology therapies through various related development projects. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Deerfield Management Company, L.P. | 30 Jun 2026 | 4,885,446 |
| Omega Fund Management, Llc | 30 Jun 2026 | 3,289,661 |
| Ecor1 Capital, Llc | 30 Jun 2026 | 2,823,126 |
| Alphabet Inc. | 30 Jun 2026 | 2,823,126 |
| Enavate Sciences Gp, Llc | 30 Jun 2026 | 2,626,946 |
| Novo Holdings A/S | 30 Jun 2026 | 2,250,000 |
| Laurion Capital Management Lp | 30 Jun 2026 | 2,002,701 |
| Armistice Capital, Llc | 30 Jun 2026 | 1,764,000 |
| Aisling Capital Management Lp | 30 Jun 2026 | 1,018,018 |
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |